NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Clinical Trials
43 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT03918278 2025-06-25
MK-0482-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03507491 2024-10-04
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Phase 1 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT04336098 2024-06-04
Study of SRF617 in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT01822314 2024-03-07
ETNA
Fondazione Michelangelo
Phase 3 Completed
NCT01325441 2023-11-15
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT01746225 2023-06-01
SNAP
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT03524898 2022-09-28
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT02862457 2022-08-19
MK-3475-434
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03275818 2022-06-07
ABRADES
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT02810418 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02138383 2021-08-17
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02280252 2020-11-23
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
NYU Langone Health
Phase 2 Completed
NCT02045602 2020-10-08
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Theriva Biologics SL
Phase 1 Completed
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT01189929 2020-09-09
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Mereo BioPharma
Phase 1 Completed
NCT02559674 2020-01-27
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
Phase 1 Completed
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT04060472 2019-08-19
Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors
Third Military Medical University
Phase 2/3 Unknown
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT02045589 2018-10-01
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
Theriva Biologics SL
Phase 1 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01219777 2018-02-08
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01964534 2017-01-31
AFUGEM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT00046423 2016-11-25
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Celgene Corporation
Phase 1 Completed
NCT00659269 2016-02-26
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
New Mexico Cancer Research Alliance
Phase 3 Completed
NCT01057264 2015-11-18
HAI Abraxane With Gemcitabine and Bevacizumab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02251951 2015-10-08
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer
Hellenic Oncology Research Group
Phase 2 Completed
NCT01161186 2012-10-11
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT00284752 2012-10-01
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Kaiser Permanente
Phase 2 Completed
NCT00466986 2011-10-12
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
Southeastern Gynecologic Oncology
Phase 2 Completed